We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Monoclonal Antibodies and Progressive Multifocal Leukoencephalopathy.
- Authors
Keene, Daniel L.; Legare, Carole; Taylor, Elaine; Gallivan, Jim; Cawthorn, Gloria Mah; Vu, Duc
- Abstract
Monoclonal antibodies have become an important treatment option for a number of serious conditions. Concerns have arisen about the potential association of these products with progressive multifocal leukoencephalopathy (PML). A list of monoclonal antibodies authorized for sale was derived from the Health Canada Drug Product Database. Case reports of PML after exposure to a monoclonal antibody authorized for use in Canada were retrieved by searching Canada Vigilance and WHO adverse event databases and through a Pub MED/Medline literature search. 182 adverse event case reports were retrieved (adalimumab -1 case, alemtuzumab-14, bevacizumab -3, cetuximab -1, efalizumab - 8, ibritumomab tiuxetan-5, infliximab-4, natalizumab-32, and rituximab-114). The Canadian Product Monographs for natalizumab and ritiximab contain box warnings for PML. A natalizumab registry has been established.
- Subjects
CANADA; MONOCLONAL antibodies; THERAPEUTICS; PROGRESSIVE multifocal leukoencephalopathy; WORLD Health Organization
- Publication
Canadian Journal of Neurological Sciences, 2011, Vol 38, Issue 4, p565
- ISSN
0317-1671
- Publication type
Article
- DOI
10.1017/S0317167100012105